These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Kee DLC; Gal J; Falk AT; Schiappa R; Chand ME; Gautier M; Doyen J; Hannoun-Levi JM Cancer Treat Rev; 2018 Nov; 70():265-271. PubMed ID: 30326422 [TBL] [Abstract][Full Text] [Related]
28. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788 [TBL] [Abstract][Full Text] [Related]
29. Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Schwartz GG Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1447-9. PubMed ID: 25085835 [TBL] [Abstract][Full Text] [Related]
30. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244 [TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer: a Cochrane systematic review. Ilic D; O'Connor D; Green S; Wilt T Cancer Causes Control; 2007 Apr; 18(3):279-85. PubMed ID: 17206534 [TBL] [Abstract][Full Text] [Related]
33. Should asymptomatic progression following definitive local treatment for prostate cancer be treated? Lillis P; Thompson IM Hematol Oncol Clin North Am; 1996 Jun; 10(3):703-12. PubMed ID: 8773506 [TBL] [Abstract][Full Text] [Related]
34. Target populations and strategies for chemoprevention trials of prostate cancer. Bostwick DG J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591 [TBL] [Abstract][Full Text] [Related]
35. Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review. Kyriakopoulos CE; Liu G Cancer J; 2016; 22(5):322-325. PubMed ID: 27749324 [TBL] [Abstract][Full Text] [Related]
36. A systematic overview of radiation therapy effects in prostate cancer. Nilsson S; Norlén BJ; Widmark A Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499 [TBL] [Abstract][Full Text] [Related]
37. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Pisansky TM Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040 [TBL] [Abstract][Full Text] [Related]
38. Clinical trials of breast and prostate cancer prevention. Greenwald P J Nutr; 2001 Jan; 131(1):176S-178S. PubMed ID: 11208959 [No Abstract] [Full Text] [Related]
39. Premalignancy in Prostate Cancer: Rethinking What we Know. De Marzo AM; Haffner MC; Lotan TL; Yegnasubramanian S; Nelson WG Cancer Prev Res (Phila); 2016 Aug; 9(8):648-56. PubMed ID: 26813971 [TBL] [Abstract][Full Text] [Related]